The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to deepen engagement between venture investors and emerging biotech companies. Chaired by Doug Dieter with Nessan Bermingham as vice chair, the council will advise BIO on policies to improve capital formation and will facilitate investor-company introductions ahead of BIO events. BIO framed the initiative as a response to a shift toward later‑stage funding and the need to rebuild pipelines of private capital for preclinical and early clinical firms. The council will also address broader policy impacts on biotech investment.